TP53 and melanoma: It should be noted that CanDrA appears to be gene- and tissue-specific, as all but one TP53 SNVs were predicted to be ‘Drivers’ by all CanDrA algorithms (that is, CanDrA breast/lung/melanoma), whereas all BRCA1 and BRCA2 SNVs were predicted to be ‘Drivers’ by CanDrA (breast) but almost exclusively ‘Passengers/No-call’ by CanDrA (lung/melanoma) (Additional file 2).